Navigation Links
Crucial Directives Must be Revised to Protect Patients' Interests and Improve Access to Treatment
Date:9/1/2011

BRUSSELS, September 1, 2011 /PRNewswire/ --

The current revision of two European Directives that are crucial to successful research into blood-related diseases must ensure the safety of patients and enhance their access to vitally-important treatment.

This was a key message of a two-day conference, "Haematology and the next European decade", hosted by the European Parliament and attended by doctors, researchers, parliamentarians, patients' organisations and Commission officials.

The revision of the Clinical Trials Directive, which provides the regulatory framework for the testing of new drugs on humans, has reached its final stages before a draft law is proposed by the European Commission within the next few months, but some politically-sensitive issues still remain.

There is a clear consensus among all stakeholders that the existing processes are overly bureaucratic, costly and time-consuming. "If we want to keep modern scientific research in Europe, we need to modernise our Directive", said Philippe Juvin MEP, the European Parliament's rapporteur on the revision.

However, haematological researchers and patients' organisations insist that seeking to reduce costs and simplify the rules in order to encourage more clinical testing in Europe must not compromise patient safety.

Also, the changes must aim to reverse the economic pressure on independent academic research - "squeezing academic research into a commercial strait-jacket" - and so facilitate a rich source of new treatments for blood-related diseases, especially rare forms of cancer.

As part of its aim to highlight the positive impact of haematology research across a range of medical conditions, the conference - organised jointly by the European Cancer Patient Coalition and the European Hematology Association, the haematologists' organisation - also discussed today the ongoing revision of the 2005 Directive relating to professional qualifications.

Both haematology researchers and patient organisations voiced concerns that respect for the free movement of medical professionals in Europe should not compromise standards of competence that could impact the safety and quality of patient care.

Haematology - a discipline covering all blood-related areas, from frequent diseases like anaemia to rare cancers, including malignant and non-malignant diseases - is always at the forefront of medical research.

It is literally vital for patients that any new EU legislation should improve co-operation for more and better-targeted funding for research in haematology, allowing haematologists to secure the research resources they need to help patients access the best possible expertise and treatment. The conference therefore aims to create grass-roots momentum for collaboration by all stakeholders at European, national and regional level to ensure this happens.

 



'/>"/>
SOURCE European Hematology Association
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Researchers at the University of Georgia Discover Protein is Crucial to Reproduction of Parasites Involved in Disease
2. Novel use of MEMS microphones to map noise pollution and meet EU directives
3. Talecris Biotherapeutics Announces Revised Record Date and Meeting Date for Special Meeting of Shareholders
4. Revised: Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials
5. Kendle to Host Conference Call to Discuss Revised 2009 Outlook
6. Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units
7. Stallergenes: Sales at end September 2008: + 17% - 2008 Sales Guidance Revised Upwards: + 14%
8. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
9. Informed Medical Communications Highlights Opportunity in Revised PhRMA Code
10. Trudeau Institute announces a discovery in how FluMist elicits protection
11. PPTA Praises Legislation That Protects the Treatment of Rare Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... HILL, N.C. , Feb. 5, 2016  In ... key role for a host of launch activities including ... importance of this launch activity is especially high in ... specialists. Best Practices and the Role of ... will help companies focused on oncology therapies find better ...
(Date:2/4/2016)... Massachusetts , February 4, 2016 - New FDA ... - New FDA action date of July 22, ... of July 22, 2016   - ... U.S. in the past decade indicated for the treatment of signs and symptoms ... Lifitegrast has the potential to be the only product approved in the U.S. ...
(Date:2/4/2016)... Feb. 4, 2016  CytoSorbents Corporation (NASDAQ: ... its flagship CytoSorb® blood filter to treat deadly ... the world, announced that CEO Dr. Phillip ... Source Capital Group,s 2016 Disruptive Growth & Healthcare ... company.  Conference Presentation Details: ...
(Date:2/4/2016)... -- Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: ... in China , today announced that ... on February 4, 2016 a preliminary non-binding proposal letter, ... PKU V-Ming ( Shanghai ) Investment Holdings ... ( Shenzhen ) Fund Management Co., Ltd., ...
Breaking Biology Technology:
(Date:1/20/2016)... Jan. 20, 2016  Synaptics Incorporated (NASDAQ: ... solutions, today announced sampling of S1423, its newest ... and small screen applications including smartwatches, fitness trackers, ... round and rectangular shapes, as well as thick ... with moisture on screen, while wearing gloves, and ...
(Date:1/11/2016)... SAN JOSE, Calif. , Jan. 11, 2016 /PRNewswire/ ... developer of human interface solutions, today announced that its ... display driver integration (TDDI) products won two separate categories ... including Best Mobile Innovator and Best Technology Breakthrough. The ... overall system cost, a simplified supply chain, thinner devices, ...
(Date:1/7/2016)... Various factors have contributed to the ... biologics and biosimilars. Some of these factors include ... demand for cost-effective alternatives, growing burden of chronic ... versions of their corresponding patented biologic drugs, and ... and efficacy. The global biosimilars market is estimated ...
Breaking Biology News(10 mins):